uniQure NV (MEX:QUREN) EBIT: MXN-2,600.4 Mil (TTM As of Mar. 2026)


MEX:QUREN uniQure NV MEX:QUREN
29 GF Score
Price MXN795.45
GF Value MXN99.43
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is uniQure NV EBIT?

uniQure NV MEX:QUREN 29 EBIT is MXN-2,600.4 Mil as of Mar. 2026. GuruFocus rates MEX:QUREN with a GF Score™ of 29/100 and a GF Value™ of MXN99.43 (Significantly Overvalued). The stock has 5 warning signs investors should review.

uniQure NV's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN-703.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-2,600.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. uniQure NV's annualized ROC % for the quarter that ended in Mar. 2026 was -88.51%. uniQure NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -617.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. uniQure NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -5.41%.

uniQure NV  (MEX:QUREN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

uniQure NV's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-3193.16 * ( 1 - 0% )/( (3712.434 + 3503.159)/ 2 )
=-3193.16/3607.7965
=-88.51 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14853.046 - 462.026 - ( 11209.286 - max(0, 1132.901 - 11811.487+11209.286))
=3712.434

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14042.172 - 502.968 - ( 10577.08 - max(0, 1067.482 - 11103.527+10577.08))
=3503.159

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

uniQure NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2814.256/( ( (474 + max(-461.162, 0)) + (437.744 + max(-487.081, 0)) )/ 2 )
=-2814.256/( ( 474 + 437.744 )/ 2 )
=-2814.256/455.872
=-617.33 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(105.567 + 0 + 496.634) - (462.026 + 0 + 601.337)
=-461.162

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(64.232 + 0 + 462.215) - (502.968 + 0 + 510.56)
=-487.081

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

uniQure NV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-2600.357/48057.782
=-5.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

uniQure NV EBIT Related Terms

uniQure NV EBIT Historical Data

* Premium members only.

The historical data trend for uniQure NV's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

uniQure NV EBIT Chart

uniQure NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,980.50 -2,272.36 -4,498.18 -3,616.09 -2,364.98

uniQure NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -573.48 -408.65 -1,012.27 -475.87 -703.56

MEX:QUREN vs NVAX, HRMY, IOVA: EBIT Comparison

For the Biotechnology subindustry, uniQure NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

uniQure NV EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where uniQure NV's EV-to-EBIT falls into.


MEX:QUREN
29GF Score
uniQure NV MEX:QUREN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

uniQure NV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-2,600.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN-2,600.4 Mil mean?
uniQure NV (MEX:QUREN) has a EBIT of MXN-2,600.4 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on uniQure NV.
Is uniQure NV's EBIT too high?
uniQure NV's current EBIT is MXN-2,600.4 Mil. Overall, uniQure NV has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's EBIT compare to NVAX and HRMY?
uniQure NV's EBIT of MXN-2,600.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on uniQure NV. uniQure NV's current EBIT is MXN-2,600.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (MEX:QUREN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN99.43, compared to a current price of MXN795.45 — trading 700% above its estimated fair value. The current EBIT is MXN-2,600.4 Mil. uniQure NV's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For uniQure NV (MEX:QUREN), the current EBIT is MXN-2,600.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is uniQure NV (MEX:QUREN) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of MXN795.45 is trading 700% above its estimated GF Value™ of MXN99.43. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for MEX:QUREN:

  • EBIT: MXN-2,600.4 Mil
  • GF Value™: MXN99.43 vs. price of MXN795.45 (700% above fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the MEX:QUREN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

uniQure NV Business Description

Other Exchanges QURE:USA0EE0:UKUQ1:Germany
Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
29GF Score

Get the complete analysis for MEX:QUREN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN795.45
Price
MXN99.43
GF Value